GPBAR1 and metabolic dysfunction-associated steatohepatitis: FXR and GPBAR1 ligands might exert beneficial effects in NASH by activating multiple mechanisms, including regulation of liver immune system in addition to lipid and glucose metabolism (6, 95) and ongoing clinical trials suggest that obeticholic acid (96, 97) as well as PX104 also known as GS-9674 (98, 99), a non-steroidal FXR ligand, exert beneficial effects in NASH.